Glycyl-l-histidyl-l-liysine-Cu(2+) loaded liposome formulations
Do you want to just say a quick word on
To better understand how the field is evolving and where it might go next DDN spoke with Jan Jezek, Chief Scientific Officer at Arecor Therapeutics, about the scientific challenges, delivery innovations, and future opportunities surrounding GLP-1 therapies
[8] Chen, Q
In a Phase 2 trial, patients taking the highest-dose combination of Wegovy and the drug, called bimagrumab, lost 22% of their weight at 72 weeks
To confirm the identify of TfR1 as a cell surface HPX-binding protein, blots of biotinylated HL-60 proteins were incubated with an anti-TfR1 antibody, then scanned and, after stripping (Yeung and Stanley, 2009), followed by streptavidinHRP and rescanned